Cargando…
Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model
Multiple myeloma (MM), a hematological malignancy of plasma cells, has remained incurable despite the development of novel therapies that improve patients’ outcome. Recent evidence indicates that the stimulator of interferon genes (STING) pathway may represent a novel target for induction of antitum...
Autores principales: | Sokolowska, Olga, Rodziewicz-Lurzynska, Anna, Pilch, Zofia, Kedzierska, Hanna, Chlebowska-Tuz, Justyna, Sosnowska, Anna, Szumera-Cieckiewicz, Anna, Sokol, Kamil, Barankiewicz, Joanna, Salomon-Perzynski, Aleksander, Ciepiela, Olga, Lech-Maranda, Ewa, Golab, Jakub, Nowis, Dominika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460740/ https://www.ncbi.nlm.nih.gov/pubmed/36044158 http://dx.doi.org/10.1007/s10238-022-00878-1 |
Ejemplares similares
-
Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity
por: Ramji, Kavita, et al.
Publicado: (2022) -
Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma
por: Sosnowska, Anna, et al.
Publicado: (2021) -
The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients
por: Barankiewicz, Joanna, et al.
Publicado: (2021) -
Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells
por: Chlebowska-Tuz, Justyna, et al.
Publicado: (2018) -
Potent but transient immunosuppression of T-cells is a general feature of CD71(+) erythroid cells
por: Grzywa, Tomasz M., et al.
Publicado: (2021)